VeriSIM Launches PulmoSIM to Develop Treatments for Rare Respiratory Diseases
March 22, 2021
Rare Daily Staff
VeriSIM Life said it launched a pharmaceutical subsidiary, PulmoSIM Therapeutics, with the mission to address the unmet needs in the treatment of rare respiratory diseases beginning with pulmonary arterial hypertension and idiopathic pulmonary fibrosis.
VeriSIM AI enabled platform delivers bio-simulations and predicts the clinical outcomes of drugs before human trials. The goal is to accurately translate, scale, and accelerate development and de-risk R&D decision-making.
The launch of PulmoSIM is the next phase in leveraging VeriSIM’s artificial intelligence platform to predict the clinical efficacy of drugs and propel drug development innovation forward.
PulmoSIM will develop breakthrough therapies for rare and progressive respiratory diseases to improve patient outcomes and quality of life. PulmoSIM’s approach modulates multiple biological pathways with a single agent, thus alleviating the need of combination therapies. With repurposing and repositioning already approved FDA drugs, PulmoSIM is targeting the underlying biology to effectively treat PAH and IPF.
“Out of more than 7,000 rare diseases, many exist in hard-to-reach peripheral regions of the respiratory system. PulmoSIM aims to leverage the immense potential drug repurposing has to offer, to tackle at least a few of these rare diseases,” said PulmoSIM scientific founder Vivek Gupta. “Development of affordable, and commercially feasible therapies is one of the many ways to improve quality of life and compliance among the patients suffering from these indications.”
Photo: Vivek Gupta, scientific founder of PulmoSIM
Sign up for updates straight to your inbox.